Tirzepatide
SURMOUNT-2
Eli Lilly · Phase 3 · Completed · Enrollment 938
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| 10 milligrams (mg) Tirzepatide | Obesity + T2D | n/r | 79 | n/r | n/r |
| 15 mg Tirzepatide | Obesity + T2D | 15 mg | 79 | n/r | n/r |
| Placebo | Obesity + T2D | n/r | 79 | n/r | n/r |
| 10 mg Tirzepatide | Obesity + T2D | 10 mg | 72 | n/r | n/r |